March 8th 2024
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
February 27th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Ofatumumab Active and Well Tolerated in Previously Untreated Follicular Lymphoma
March 18th 2019Ofatumumab was both active and well-tolerated at 2 different dose levels in treatment-naïve patients with advanced follicular lymphoma who had low tumor burden, according to findings from a phase II, multicenter study recently published in the <em>British Journal of Haematology</em>.
Read More
Expert Highlights Early Efficacy Seen With Mosunetuzumab in Follicular Lymphoma and DLBCL
February 28th 2019In an interview with <em>Targeted Oncology </em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.
Read More
Fowler Highlights Trials Accruing at MD Anderson for Relapsed/Refractory Follicular Lymphoma
February 28th 2019In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.
Read More
Expert Highlights Ongoing Research Efforts to Advance Treatment Paradigm in Follicular Lymphoma
February 27th 2019In an interview with <em>Targeted Oncology, </em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.
Read More
Based on data from the phase III AUGMENT trial, a supplemental new drug application for the R<sup>2</sup> regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.
Read More
Results of a multi-institutional, retrospective analysis showed that radiotherapy in localized follicular lymphoma resulted in 68.9% of patients having no disease progression at 5 years with fewer than 2% of patients experiencing an in-field relapse, according to a study published in <em>Blood</em>.
Read More
A new retrospective analysis of 640 newly diagnosed patients with follicular lymphoma found that patients who had achieved partial remission after 4 or more cycles of bendamustine plus rituximab experienced improved duration of response on maintenance rituximab compared with patients who received no maintenance treatment or who were in complete remission following induction with bendamustine plus rituximab.
Read More
Obinutuzumab Lowers Incidence of Disease Progression in Follicular Lymphoma
January 29th 2019According to an exploratory analysis of the GALLIUM trial, obinutuzumab-based chemotherapy resulted in fewer incidences of disease progression compared to rituximab-based chemotherapy in previously untreated patients with advanced follicular lymphoma.
Read More
Results From the Phase III AUGMENT Trial in Recurrent Indolent Lymphomas
December 28th 2018John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.
Watch
Cohen Highlights the Factors That Influence Treatment Choice in Case Study of Advanced cHL
December 28th 2018During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma
Read More
Lymphoma Continues to be Main Cause of Death in Follicular Lymphoma, New Pooled Analysis Finds
December 27th 2018A new pooled analysis concluded that the leading cause of death in patients with follicular lymphoma continues to be lymphoma, despite the widespread improvements in overall survival demonstrated with rituximab.
Read More
Overview of R2 Regimen for Relapsed Follicular Lymphoma
December 27th 2018Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br />
Watch
Cohen Reviews Current Treatment Options in a Case Study of High-Risk Follicular Lymphoma
December 27th 2018Jonathon B. Cohen, MD, MS, recently discussed treatment considerations and decisions in the case of a patient with follicular lymphoma. Cohen discussed the case scenario during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Modest Benefit Found With Addition of Durvalumab to Ibrutinib in R/R FL and DLBCL
December 20th 2018The combination of ibrutinib and durvalumab demonstrated a modest clinical benefit for patients with relapsed or refractory follicular lymphoma and germinal center B-cell diffuse large B-cell lymphoma, according to the results of a phase I/II trial.
Read More